tbuckley/cabot-search huggingface dataset:
<i>EPAS1</i> Mutations and Paragangliomas in Cyanotic Congenital Heart Disease
Authors: Anand Vaidya, Shahida K Flores, Zi-Ming Cheng, Marlo Nicolas, Yilun Deng, Alexander R Opotowsky, Delmar M Lourenço, Justine A Barletta, Huma Q Rana, M Adelaide Pereira, Rodrigo A Toledo, Patricia L M Dahia
Journal: New England Journal of Medicine (2018)

Paraganglioma, HIF-2α, and Cyanotic Heart Disease Four of five patients with paragangliomas and pheochromocytomas who had received a diagnosis of congenital cyanotic heart disease had mutant HIF-2α. This contrasts with the prevalence of mutant HIF-2 in these tumor types in the absence of cyanotic heart disease (6 to 10%).
THE PREVALENCE OF GASTRIC POLYPS INCIDENTALLY DISCOVERED DURING ENDOSCOPY
Authors: M Monalisa Filip, M Caliţa, ED Burtea, S Iordache, DM Traşcă, A Săftoiu
Journal: Endoscopy (2018)

Gastric polyps are preneoplastic lesions, often asymptomatic, discovered incidentally during endoscopic examinations. Recent epidemiological studies show a low prevalence of gastric polyps in population, but with an increasing frequency of fundic gland polyps probably due to the long-term use of proton pump inhibitors. The aim of this study was to analyze the prevalence and histopathological type of gastric polyps found at endoscopy in daily practice.
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
Authors: Yue Zhao, Timothy Wai Ho Shuen, Tan Boon Toh, Xue Ying Chan, Min Liu, Sue Yee Tan, Yong Fan, Hechuan Yang, Shridhar Ganpathi Lyer, Glenn Kunnath Bonney, Eva Loh, Kenneth Tou En Chang, Thiam Chye Tan, Weiwei Zhai, Jerry Kok Yen Chan, Edward Kai-Hua Chow, Cheng Ean Chee, Guan Huei Lee, Yock Young Dan, Pierce Kah-Hoe Chow, Han Chong Toh, Seng Gee Lim, Qingfeng Chen
Journal: Gut (2018)

As the current therapeutic strategies for human hepatocellular carcinoma (HCC) have been proven to have limited effectiveness, immunotherapy becomes a compelling way to tackle the disease. We aim to provide humanised mouse (humice) models for the understanding of the interaction between human cancer and immune system, particularly for human-specific drug testing.
HEMOSPRAY: DESCRIPTIVE STUDY ABOUT ITS APPLICATION ON GASTROINTESTINAL BLEEDING IN A UNIVERSITY HOSPITAL
Authors: L Peries, I Serra, M Albert, D Busquets, C Huertas, H Ikuo Uchima, O Miquel, O Retto, L Torrealba, C Luz Rosales, C Coll, RF Louvrieux, X Aldeguer
Journal: Endoscopy (2018)

Gastrointestinal bleeding (GIB) is the most frequent indication to perform an emergent endoscopy. Although all different techniques available, acute hemostasis is not always achieved. During last years, Hemospray has become a promising technique to control the bleeding. The aim of this study is to describe the experience using Hemospray technique in our hospital.
<i>Notes from the Field</i>: Fatalities Associated with Human Adenovirus Type 7 at a Substance Abuse Rehabilitation Facility — New Jersey, 2017
Authors: Faye Rozwadowski, Mardea Caulcrick-Grimes, Lisa McHugh, AnnMarie Haldeman, Tara Fulton, Marie Killerby, Eileen Schneider, Xiaoyan Lu, Senthilkumar K. Sakthivel, Julu Bhatnagar, Demi B. Rabeneck, Sherif Zaki, John Watson
Journal: MMWR Morbidity and Mortality Weekly Report (2018)
CARBON DIOXIDE INSUFFLATION DURING ENDOSCOPIC RESECTION OF LARGE COLORECTAL POLYPS CAN REDUCE POST-PROCEDURE ABDOMINAL PAIN
Authors: JW Chung, SY Kim, JH Kim, YJ Kim, KO Kim, KA Kwon, DK Park
Journal: Endoscopy (2018)

Compared to air insufflation, carbon dioxide (CO2) insufflation reduces abdominal pain after endoscopic procedures. However, studies of the use of CO2 insufflation during endoscopic resection of large colorectal polyps (LCPs) are lacking. This study evaluated the impact of CO2 insufflation on pain after endoscopic resection of LCPs.
Contrast-Enhanced Endoscopic Ultrasonography (CE-EUS) Improves Visualization of Pancreatic Vasculature
Authors: S Giday, P Magno, M Canto, J Buscaglia, J Clarke, L Wroblewski, A Kalloo, S Kantsevoy, S Jagannath
Journal: Endoscopy (2006)

Neovascularization in neoplasms may enable improved visualization with EUS if a contrast agent is used. Lipid microspheres are an established diagnostic tool for increasing contrast of vascular structures in echocardiography. Aim: To evaluate the potential utility of contrast enhanced EUS (CE-EUS) in the characterization of pancreatic lesions in a porcine model. Methods: 3 anesthesized 50kg pigs underwent EUS. For optimal visualization, the ultrasound mechanical index was decreased to 0.3. 2 mL of Perflutren lipid microspheres (5uL/kg) (Definity®) were administered by peripheral IV. The pancreas and peri-pancreatic vessels were re-imaged. To create an animal model of pancreatic microvascular disruption, 0.5 mL of 50% ethanol plus purified carbon particle solution (GI Spot®) was injected with an Olympus® 22g EUS-FNA needle into the body of the pancreas. 24–48 hours post ethanol-injection, the pancreas was re-evaluated. Standard and CE-EUS imaging of the pancreas were compared. Post-mortem examination was performed. Results: With conventional EUS, there was minimal color flow within the pancreatic parenchyma. Within 30 seconds of injection of microspheres, the microvasculature of the pancreas was well visualized with increased color flow. The microspheres were also well seen in the peri-pancreatic vessels. The mean duration CE-EUS visualization was 2.29 minutes. Standard EUS imaging showed a subtle 1cm hypoechoic region in the ethanol-treated area. Color and power doppler EUS of this region did not reveal any signal or blood flow. After microsphere injection, color Doppler EUS revealed marked contrast enhancement of normal pancreatic parenchyma from the alcohol-treated area, which on groß examination corresponded to the marked necrotic area. Conclusions: CE-EUS with microspheres improves EUS visualization of the pancreatic microvasculature and delineation of altered vascular perfusion.
A LOOK INTO THE REPORTING OF PERFORMANCE MEASURES FOR LOWER GASTROINTESTINAL ENDOSCOPY FROM A TERTIARY REFERRAL CENTER FROM ROMANIA: ROOM TO IMPROVE
Authors: D Bobeică, T Voiosu, A Benguş, M Rimbaş, B Mateescu, A Voiosu
Journal: Endoscopy (2018)

Standardized reporting and formal quality benchmarking for lower gastrointestinal (GI) endoscopy are essential to ensure quality services but are currently deficient in Romania. We aimed to analyze data regarding quality in colonoscopy practices in a single referral center in order to identify areas which require oversight and improvement.
ENDOSCOPIC SUBMUCOSAL DISSECTION OF A SUSPICIOUS ESOPHAGEAL LESION
Authors: L Mans, AM Bucalau, P Eisendrath, L Verset, P Demetter, V Huberty, A Demols, J Devière, A Lemmers
Journal: Endoscopy (2018)

A 80-year-old woman, hospitalized for atrial fibrillation and cardiac decompensation, presented anemia and melena during her stay. An esogastroduodenoscopy revealed a 2 × 2 cm Paris type 0-IIa+IIc neoplastic lesion at 30 to 32 cm from the incisors. The IPCL pattern analysis with NBI and near focus revealed V-3 type suggesting the presence of submucosal infiltration. The biopsy revealed a poorly differentiated squamous cell carcinoma. Endoscopic ultrasound disclosed a 15 mm mucosal lesion with extension in the submucosa (uT1N0Mx). There was no distant metastasis on work-up (thoracic and abdominal CT scan, bronchoscopy and PET CT).
Genetic association studies and the risk factors for developing the “Immuno‐bile‐logic” disease primary biliary cholangitis
Authors: Evaggelia Liaskou, Gideon M. Hirschfield
Journal: Hepatology (2017)

1Centre for Liver Research and NIHR Birmingham Biomedical Research CentreInstitute of Immunology and Immunotherapy University of BirminghamBirminghamUK 2Institute of Translational Medicine, Birmingham Health PartnersUniversity Hospitals BirminghamBirminghamUK *ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:Gideon M. HirschfieldCentre for Liver Research and NIHR Birmingham Biomedical Research CentreUniversity of BirminghamBirmingham, UK[email protected]
The roles of intraductal US in acute biliary pancreatitis patients without choledocholithiasis on ERCP
Authors: JH Moon, YK Cheon, YD Cho, JO Kim, JS Lee, MS Lee, HK Lee, CS Shim, BS Kim
Journal: Endoscopy (2006)

Background/Aim: ERCP is considered the standard for the detection of bile duct stones, but small stones may not be detected in patients with biliary pancreatitis. Failure to image stones may lead to recurrent attacks of pancreatitis. Intraductal US (IDUS) is easily performed during the same endoscopic session as ERCP without sphincterotomy. The aim of this study was to prospectively evaluate the ability of IDUS for detecting small stones in patients with biliary pancreatitis having no choledocholithiasis by ERCP. Methods: 37 patients with suspicious acute biliary pancreatitis were studied. All patients had no evidence of bile duct stones on ERCP. ERCP was performed within 24 hours of admission for ten patients having severe pancreatitis and within 72 hours in patients with mild attacks. Wire-guided IDUS was performed during ERCP in all patients. The outcomes of IDUS were compared with the results of endoscopic extraction as the reference standard for choledocholithiasis and sludge. Results: 1) nine (24.3%) patients had small bile duct stones (<3mm) on IDUS. IDUS revealed sludge in eight (21.6%) patients. All stones and sludge were confirmed after sphincterotomy and extraction. 2) Choledocholithiasis was more frequent in patients with bile duct dilatation (>10mm) and cholelithiasis (p<0.05). 3) Cholelithiasis was combined in 30 (81.1%) patients. Among them, 21 patients performed laparoscopic cholecystectomy and two patients performed cholangioscopic stone removal. 4) With a median follow-up of 26.8 months, two patients having cholelithiasis without treatment developed recurrent pancreatitis. Conclusion: Intraductal US can be considered reliable for the detection of small choledocholithiasis in patients with biliary pancreatitis. IDUS may be useful to reduce the risk of recurrent pancreatitis after treatment.
ST-Segment Elevation in Lead aVR
Authors: Jorge A. Brenes-Salazar
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
ADVANCED ENDOSCOPIC MANAGEMENT OF SEVERE, COMPLEX BARIATRIC SURGERY COMPLICATIONS
Authors: A Martínez-Alcalá García, PT Kröner, AM Ahmed, MA D'Assunção, I Jovanovic, K Mönkemüller
Journal: Endoscopy (2018)

The aim of this study was to evaluate the success, safety and complications rates of advanced endoscopy for the management of bariatric surgery complications.
HIGHER HAREFIELD CLEANSING SCALE SCORES ARE ASSOCIATED WITH IMPROVED LESION DETECTION: POST HOC ANALYSIS OF THREE RANDOMISED AND CENTRAL READER-ASSESSED PHASE 3 CLINICAL TRIALS
Authors: J Manning, C Hassan, J Halonen, B Amlani, M Epstein
Journal: Endoscopy (2018)

Effective colonoscopy requires successful bowel cleansing. The bowel preparation NER1006 (PLENVU®) was assessed in three identically designed randomised phase 3 clinical trials. These trials used validated cleansing scales and treatment-blinded central readers for a standardised cleansing quality assessment. This post hoc analysis assessed the relationship between colon cleansing quality using the Harefield Cleansing Scale (HCS), and overall colon detection rates for adenomas (ADR) and polyps (PDR).
The usefulness of visual assessment for adequacy of endosonography-guided fine needle aspiration cytology
Authors: Eum Junbum
Journal: Endoscopy (2011)

Endosonography-guided fine needle aspiration (EUS-FNA) is useful in the diagnosis and staging of pancreatobiliary or gastrointestinal malignancy. It has been reported that on-site cytopathologic interpretation improves sample adequacy. However, it is difficult to get support from on-site cytopathologists in general practice. Thus, we conducted this study to find out whether simple visual assessment is useful enough to predict the adequacy of EUS-FNA.
NOVEL TECHNIQUE FOR DIRECT PERCUTANEOUS ENDOSCOPIC JEJUNOSTOMY TUBE PLACEMENT USING SINGLE BALLOON ENTEROSCOPY WITH FLUOROSCOPY IN PATIENTS WITH SURGICALLY ALTERED UPPER GI TRACT ANATOMY
Authors: A Martínez-Alcalá García, T Kroner, JP Gutierrez, I Jovanovic, M D'Assunção, L Fry, K Mönkemüller
Journal: Endoscopy (2018)

Direct percutaneous endoscopic jejunostomy (DPEJ) is a useful method to deliver nutrition in patients with a variety of problems such as: malignancies causing gastric outlet obstruction, gastroparesis, pancreatitis, high risk of aspiration and malnutrition, malnutrition in the setting of prior complex post-upper GI tract surgery such as gastric resection or Roux-en-Y gastric bypass. DPEJ using standard colonoscopes or push technique remains a technically challenging procedure, with success rates in expert hands being around 68%. Hereby we present the key steps to successfully conduct a DPEJ using single balloon enteroscopy technique.
Evaluation in vivo, en temps réel, de la structure et des mouvements contractiles des villosités duodénales dans la maladie coeliaque par l'endocytoscopie
Authors: T Matysiak-Budnik, E Coron, JF Mosnier, M Le Rhun, H Inoue, JP Galmiche
Journal: Endoscopy (2009)

Introduction: Le diagnostic de la maladie coeliaque (MC) repose sur la mise en évidence d'une atrophie villositaire au niveau des biopsies duodénales. Ce diagnostic peut être difficile à cause d'une mauvaise orientation des biopsies et d'un risque d'erreur d'échantillonnage en cas d'atrophie en aires. Notre étude préliminaire a montré que l'endocytoscopie (EC), une nouvelle technique d'endoscopie en großissement permettant de visualiser la muqueuse digestive à l'échelle microscopique in vivo, permet de distinguer facilement la muqueuse duodénale normale de la muqueuse atrophique. Le but de cette étude a été d'évaluer la performance diagnostique de l'EC dans la MC et sa capacitéà détecter les anomalies fonctionnelles de la muqueuse duodénale non accessibles à l'examen anatomo-pathologique standard.
First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
Authors: Ugur Sahin, Dirk Jaeger, Frederik Marme, Athanasios Mavratzas, Jürgen Krauss, Jacques De Greve, Ignace Vergote, Oezlem Tureci
Journal: Journal of Clinical Oncology (2015)

5537 Background: Ovarian cancer (OC) is a high medical need disease. Most patients (pts) relapse following initial therapy with limited therapeutic options. IMAB027 is the first-in-class monoclonal antibody (mAB) directed against claudin 6 (CLDN6), a cancer cell specific, embryonic tight junction protein and cancer stem cell marker. CLDN6 is expressed in > 55% of OCs and frequently in other cancer types. In preclinical models, IMAB027 executes potent anti-tumor activity via AB-dependent cellular cytotoxicity and complement-dependent cytotoxicity without mediating off-target toxicity. Methods: This first-in-human, open-label, dose escalation Phase I/II trial assesses the safety/tolerability (NCI-CTCAEv4.0), pharmacokinetics (PK) and clinical efficacy (RECIST 1.1) of IMAB027 in pts with advanced, recurrent CLDN6+ OC. Here we report preliminary data on 12 pts enrolled in the Phase I part of the study as of August 15, 2014. Pts received 100, 300, 600, or 1000 mg/m2 IMAB027 (n = 3/group) q3w IV until disease progression. Results: Pts had a median age of 64 (54–75) years, platinum-resistant disease and had received a median of 4 (3–9) lines of previous chemotherapies. All administered doses were safe and well tolerated, no DLT was observed and the MTD was not reached. 108 AEs have been recorded, all but 5 (4 grade [gr] 3, 1 gr 4) were gr 1–2 (82 and 21 AEs, respectively). 29 AEs were considered IMAB027 related (22 gr 1, 6 gr 2, 1 gr 3 as deemed by investigator). Five AEs (all in 1 pt) were classified as SAEs incl. one gr 2 hypersensitivity (study drug-related SUSAR). IMAB27-related SAEs were manageable and fully resolved. IMAB027 PK was well described with a 2-compartment model (mean AUC: 20,770–86,160 µg/mL×h; mean Cmax: 151–611 µg/mL for 300–1000 mg/m2). First signs of IMAB027 clinical activity were observed. Conclusions: This is the first clinical study to show effects of a therapy targeting CLDN6. Based on these preliminary Phase I data, IMAB027 may present a safe and well tolerated treatment option for women with recurrent, advanced OC. This warrants further clinical evaluation of IMAB027 in this patient population with a high medical unmet need. Clinical trial information: NCT02054351.
Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial
Authors: Menno R Smit, Eric O Ochomo, Ghaith Aljayyoussi, Titus K Kwambai, Bernard O Abong'o, Tao Chen, Teun Bousema, Hannah C Slater, David Waterhouse, Nabie M Bayoh, John E Gimnig, Aaron M Samuels, Meghna R Desai, Penelope A Phillips-Howard, Simon K Kariuki, Duolao Wang, Steve A Ward, Feiko O ter Kuile
Journal: The Lancet Infectious Diseases (2018)
Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).
Authors: Mei Sim Lung, Michael Hofman, Grace Kong, Sue-Ping Thang, Michael Michael, Rodney J Hicks
Journal: Journal of Clinical Oncology (2017)

e15694 Background:Grade 3 (G3) NETs have a poor prognosis and limited treatment options (usually chemotherapy). PRRT is a potential treatment option if all sites of disease demonstrate high uptake on somatostatin-receptor imaging (SSRI). We retrospectively evaluated the efficacy of PRRT in G3 NETs. Methods: We reviewed records of patients with metastatic G3 NETs (Ki-67 &gt; 20%) who received PRRT at our institution. Patients were treated with up to 5 cycles of PRRT, predominantly 177 Lu-DOTA-octreotate. Further maintenance PRRT was administered upon progression if deemed suitable on SSRI. Radio-sensitizing chemotherapy was administered unless contra-indicated. Kaplan-Meier estimate was used to determine median overall survival (OS) and median time to new treatment/death (TNTD) defined from start of PRRT. Subgroup-analysis was performed for patients with Ki67 &lt; 55% and ≥55%. Results: 26 patients with metastatic G3 NET received PRRT; 22 combined with chemotherapy (capecitabine/temozolomide (n = 12), 5-fluorouracil or capecitabine (n = 8), other (n = 2)). 58% were male. The median age was 62 (range 16-78 years). 61% had pancreatic NET, 19% small bowel, 8% lung, 8% unknown primary, 4% rectal. 77% had received at least one line of prior chemotherapy. 54% received prior platinum-based chemotherapy. Median follow-up was 33 months (range 8-83 months). Patients received a median of 4 cycles of PRRT (range 1-15). The estimated median OS from start of PRRT was 18 months: for Ki-67 &lt; 55% (n = 21), 20 months; and Ki-67≥ 55% (n = 5), 9 months. The estimated median TNTD was 12 months: for Ki-67 &lt; 55%, 16 months; and Ki-67≥55%, 4 months. 31% of patients were alive without a change in treatment modality following PRRT. Conclusions: In thispoor prognosis G3 NET cohort of whom 77% had received prior chemotherapy, a median OS of 18 months from start of PRRT is encouraging and warrants further study. PRRT is a promising treatment option for patients with G3 NET with high somatostatin-receptor expression selected by SSRI.
PREOPERATIVE PREDICTIVE MODEL FOR EN BLOC COLORECTAL ESD (CR-ESD): A SPANISH PROSPECTIVE MULTICENTRE COHORT STUDY
Authors: JC Marín-Gabriel, F Ramos-Zabala, F Múgica-Aguinaga, E Albéniz Arbizu, J de la Peña-García, A Sánchez-Yagüe, C Dolz-Abadía, G Fernández-Esparrach, A Álvarez-Delgado, Á Terán-Lantarón, H Cortés-Pérez, AJ del Pozo-García, J Díaz-Tasende
Journal: Endoscopy (2018)

The demographic and clinical characteristics of the patients and lesions were prospectively collected. Morphological features of the tumors and technical factors were recorded.
Etude prospective monocentrique des facteurs de risque de polypes colorectaux: adénomes avancés, adénomes, polypes hyperplasiques
Authors: U Chaput, S Alberto, G Baron, P Ravaud, F Beuvon, B Terris, R Coriat, M Bensoussan, H Roche, M Gaudric, F Prat, S Chaussade
Journal: Endoscopy (2009)

Introduction: Un adénome avancé colorectal est un adénome défini par sa taille (≥10mm de grand axe) et/ou ses caractéristiques histologiques (présence d'un contingent villeux et/ou d'une dysplasie sévère et/ou d'un carcinome in situ). L'adénome avancé est la lésion colique comportant le plus haut risque d'évolution vers un adénocarcinome colorectal (30%). Les facteurs de risque reconnus d'adénome avancé colorectal sont: l'âge, le sexe masculin et les antécédents familiaux de cancer colorectal. Il a été récemment suggéré que certains facteurs de risque cardio-vasculaires pourraient être associés à la présence d'adénomes et d'adénomes avancés colorectaux. L'objectif de notre étude était de comparer les patients adressés pour coloscopie dans un centre d'endoscopie en fonction des polypes coliques retrouvés et de rechercher une association entre la présence de facteurs de risques cardio-vasculaires et ces différents types de polypes.
GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor Growth
Authors: Leanne Li, Qiqun Zeng, Arjun Bhutkar, José A. Galván, Eva Karamitopoulou, Daan Noordermeer, Mei-Wen Peng, Alessandra Piersigilli, Aurel Perren, Inti Zlobec, Hugh Robinson, M. Luisa Iruela-Arispe, Douglas Hanahan
Journal: Cancer Cell (2018)

Genetic linkage analysis previously suggested that GKAP, a scaffold protein of the N-methyl-D-aspartate receptor (NMDAR), was a potential modifier of invasion in a mouse model of pancreatic neuroendocrine tumor (PanNET). Here, we establish that GKAP governs invasive growth and treatment response to NMDAR inhibitors of PanNET via its pivotal role in regulating NMDAR pathway activity. Combining genetic knockdown of GKAP and pharmacological inhibition of NMDAR, we implicate as downstream effectors FMRP and HSF1, which along with GKAP demonstrably support invasiveness of PanNET and pancreatic ductal adenocarcinoma cancer cells. Furthermore, we distilled genome-wide expression profiles orchestrated by the NMDAR-GKAP signaling axis, identifying transcriptome signatures in tumors with low/inhibited NMDAR activity that significantly associate with favorable patient prognosis in several cancer types.
Effective anti-programmed death-1 therapy in a<i>SUFU</i>-mutated patient with Gorlin-Goltz syndrome
Authors: A. Moreira, M.C. Kirchberger, F. Toussaint, M. Erdmann, G. Schuler, L. Heinzerling
Journal: British Journal of Dermatology (2018)

We present the case of a 77‐year‐old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off‐label therapy with the anti‐programmed death‐1 antibody pembrolizumab after four infusions.